SCIENTIFIC AND STRATEGIC ADVISORY

Can this asset become a differentiated medicine?

Can this asset become a differentiated medicine?

Can this asset become a differentiated medicine?

BioArtemis helps biotech leaders, investors and pharma teams determine whether compelling science can become a clinically credible, globally executable and partnerable medicine—and what evidence, development strategy and capabilities are required to get it there.

BioArtemis helps biotech leaders, investors and pharma teams determine whether compelling science can become a clinically credible, globally executable and partnerable medicine—and what evidence, development strategy and capabilities are required to get it there.

Discuss an asset

Explore Global Asset Readiness

Biology → Translation → Clinical asset → Phase 2/3 → Differentiated medicine → Launch → Partnerability

Biology → Translation → Clinical asset → Phase 2/3 → Differentiated medicine → Launch → Partnerability

Selected experience across global pharma, biotech and independent advisory

Selected experience across global pharma, biotech and independent advisory

SELECTED EXECUTIVE EXPERIENCE

Pfizer Novartis Celgene Biogen Alnylam Mayne Pharma Rejuveron Life Sciences

INDEPENDENT INNOVATION EVALUATION

Independent evaluation: Innosuisse Innovation Expert

SELECTED CONSULTING AND ADVISORY EXPERIENCE

Pfizer OxThera Nektar Therapeutics Cyclarity Therapeutics Cortex Discovery Nanotics In Virtuo Laboratories

Scientific promise is not the same as asset readiness.

Scientific promise is not the same as asset readiness.

Scientific promise is not the same as asset readiness.

An asset may be biologically compelling yet remain vulnerable on human translation, patient selection, clinical differentiation, pivotal evidence or future partner scrutiny. BioArtemis examines the programme vertically—from its scientific foundations to the medicine it must ultimately become.

Can the biology credibly translate into humans?

Can the clinical asset become a differentiated medicine for a defined patient population?

Would a future partner want to inherit the programme?

GLOBAL ASSET READINESS

Global Asset Readiness

Global Asset Readiness

Global Asset Readiness

BioArtemis pressure-tests the assumptions that determine whether an asset can progress, differentiate and withstand investment, development and partnering scrutiny.


Global Asset Readiness provides an independent, integrated evaluation of the scientific, clinical, competitive and strategic assumptions that determine an asset’s future value and partnerability.

BioArtemis pressure-tests the assumptions that determine whether an asset can progress, differentiate and withstand investment, development and partnering scrutiny.


Global Asset Readiness provides an independent, integrated evaluation of the scientific, clinical, competitive and strategic assumptions that determine an asset’s future value and partnerability.

01 SCIENTIFIC READINESS

Biology, target, mechanism and robustness of evidence

02 TRANSLATIONAL READINESS

Human relevance, biomarkers, pharmacodynamic evidence and patient-selection rationale

03 CLINICAL READINESS

Indication, patient population, dose rationale, endpoints and proof of concept

04 DIFFERENTIATION READINESS

Competition, standard of care and clinically meaningful advantage

05 LATE-STAGE READINESS

Phase 2/3 evidence, pivotal assumptions, comparator relevance and global relevance

06 MEDICINE READINESS

Who should receive the medicine, when, why and how it changes practice

07 LAUNCH READINESS

Evidence, scientific positioning, external experts, medical strategy and organisational capability

08 PARTNERABILITY

Due-diligence resilience, strategic attractiveness, value-creation potential and remaining risk

One asset. Decisions across its full trajectory.

One asset. Decisions across its full trajectory.

One asset. Decisions across its full trajectory.

Early assets

Evaluate biological rationale, target validation, disease relevance, preclinical evidence, human relevance, biomarkers and competitive differentiation.

Translational and early clinical evidence

Assess indication rationale, patient selection, biomarkers, proof of mechanism, proof of concept, dose rationale and endpoint relevance.

Phase 2/3 and medicine strategy

Pressure-test patient population, endpoints, comparator relevance, benefit-risk, clinical differentiation and the evidence supporting pivotal decisions.

Launch and partnerability

Assess how the future medicine should be positioned: its scientific narrative, treatment pathway, evidence needs, organisational capabilities and what a future partner would want to inherit.

STRATEGIC DECISIONS BEYOND A SINGLE MILESTONE

Portfolio and global expansion decisions begin with the asset.

Portfolio and global expansion decisions begin with the asset.

BioArtemis helps leadership teams determine which assets merit further investment, how portfolios should be prioritised, and whether an asset is ready to progress, partner or expand across major markets.

PORTFOLIO DECISIONS

Compare scientific and clinical evidence, differentiation, remaining risk and evidence requirements across assets. Support portfolio prioritisation, investment decisions, stage gates and build, partner or stop decisions.

GLOBAL EXPANSION READINESS

Before asking how to enter the US or Europe, determine whether the asset itself is ready for US and European scientific, clinical and partner scrutiny. Identify the evidence, adaptations and organisational capabilities required for credible expansion.

Geographic ambition cannot compensate for an asset that is not yet globally ready.

ENTRY MANDATE

Global Asset Readiness Review

Global Asset Readiness Review

A focused, independent senior assessment integrating scientific, clinical, competitive and strategic evidence for leadership teams approaching a consequential asset decision.

Discuss a Global Asset Readiness Review

What is strong
What is fragile
What remains unproven
What partners will challenge
What evidence would change the decision
What should happen next

Dr Siham Ceballos, Founder of BioArtemis

SIHAM CEBALLOS, PhD, MBA · FOUNDER

Scientific depth. Executive judgement. Focused on the medicine.

Scientific depth. Executive judgement. Focused on the medicine.

Scientific depth. Executive judgement. Focused on the medicine.

Siham Ceballos, PhD, MBA, combines molecular and cellular biology with more than 20 years of leadership across pharma and biotech, building international Medical Affairs organisations, launch capabilities and biotech ventures while working with assets from Phase 2/3 through launch, portfolio evaluation and independent innovation assessment.

Her perspective connects science, clinical evidence, medical strategy, launch and global implementation. This allows BioArtemis to examine an early asset in light of what it must eventually become as a medicine—and to challenge a late-stage programme without losing sight of its underlying biology.

Scientist
Biotech executive & builder
Medical Affairs & launch leader builder
Asset and portfolio evaluator

CONFIDENTIAL DISCUSSION

An important asset decision deserves an independent challenge.

An important asset decision deserves an independent challenge.

An important asset decision deserves an independent challenge.

BioArtemis works with biotech CEOs, founders, boards, CBOs, CMOs, investors, and pharma Business Development and Search & Evaluation teams.

Typical discussions involve portfolio choices, asset progression, partnering, financing, or global expansion.

BioArtemis works with biotech CEOs, founders, boards, CBOs, CMOs, investors, and pharma Business Development and Search & Evaluation teams.

Typical discussions involve portfolio choices, asset progression, partnering, financing, or global expansion.

Start a confidential discussion

Email: siham.ceballos@bioartemis.com

LinkedIn: Connect on LinkedIn